10:33 AM EDT, 04/28/2025 (MT Newswires) -- Galmed Pharmaceuticals ( GLMD ) said Monday it has signed a binding term sheet with Entomus for a license deal to develop and commercialize a novel semaglutide sublingual formulation.

The formulation is based on Self-Emulsifying Drug Delivery System which is absorbed sublingually into the lymphatic system, the company said.

The formulation would offer alternatives to injectable semaglutide and oral form, providing a non-invasive route that allows the medication to enter the bloodstream through the oral mucous membranes, Galmed said.

The company said a definitive agreement is to be executed within 90 days.

Galmed shares were up about 45% in recent trading.

Price: 2.26, Change: +0.69, Percent Change: +43.95